Cancer

News

Ipsen warns over medicine supplies amid Brexit uncertainty

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines.

News

Astellas gains three cancer drugs with $405m Potenza buy

Astellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three years working together on cancer immunotherapies.

News

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%.

News